Clinical Trials Logo
  1. Home
  2. Stage IV Pleural Mesothelioma
  3. NCT02568449

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Recurrent Pleural Malignant Mesothelioma Clinical Trial

Official title:
A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma

Clinical Trial Summary

This phase II trial studies how well nintedanib works in treating patients with malignant pleural mesothelioma that has come back. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To assess the 4-month progression-free survival (PFS) in patients with recurrent, unresectable malignant pleural mesothelioma (MAM) treated with nintedanib. SECONDARY OBJECTIVES: I. To assess response rate (confirmed and unconfirmed, complete and partial responses) and disease control rate (response or stable disease) in the subset of patients with measurable disease by both RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria and Modified RECIST criteria for pleural tumors. II. To assess overall survival. III. To evaluate the frequency and severity of toxicities associated with this treatment regimen. IV. To collect tissue samples for future correlative studies related to overall study objectives. OUTLINE: Patients receive nintedanib orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02568449
Study type Interventional
Source Barbara Ann Karmanos Cancer Institute
Contact
Status Completed
Phase Phase 2
Start date March 15, 2016
Completion date June 26, 2018
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02408016 - Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma Phase 1/Phase 2
Active, not recruiting NCT02535312 - Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Phase 1/Phase 2
Active, not recruiting NCT02399371 - Pembrolizumab in Treating Patients With Malignant Mesothelioma Phase 2
Active, not recruiting NCT03074513 - Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Phase 2